Hallak H O, Wedlund P J, Modi M W, Patel I H, Lewis G L, Woodruff B, Trowbridge A A
College of Pharmacy, University of Kentucky, Lexington 40536-0082.
Br J Clin Pharmacol. 1993 Mar;35(3):327-30. doi: 10.1111/j.1365-2125.1993.tb05703.x.
A 30 year old black male required a 60 mg daily dose of warfarin to elicit a therapeutic anticoagulant response (normal warfarin dose 2.5-10 mg day-1; maximum 15 mg day-1). Hereditary warfarin resistance was suspected after compliance, diet, concurrent medication and any gastrointestinal disorder were eliminated as contributory causes. The disposition of vitamin K and vitamin K epoxide was examined in the propositus, his two sisters and 13 control black male subjects. Each subject was given an i.v. bolus dose (5 mg) of vitamin K prior to and after 2 weeks of warfarin therapy (5 mg day-1). The oral clearances of (S)- and (R)-warfarin were also measured in each subject during the last day of warfarin therapy. The mean (+/- s.d.) systemic clearance of vitamin K was similar in all subjects before (114 +/- 35 ml min-1) and after (112 +/- 40 ml min-1) warfarin therapy. The mean (+/- s.d.) AUC value for vitamin K epoxide was increased by warfarin treatment (6.5 +/- 5.4 micrograms ml-1 min before and 139 +/- 78 micrograms ml-1 min after) in all subjects. In the propositus, the oral clearance of (S)-warfarin (14.5 ml min-1) and the clearance ratio for (S)/(R)warfarin (2.6) differed by more than 7 standard deviations from the control group (4.3 +/- 1.1 ml min-1 and 1.2 +/- 0.2, respectively). In one sister of the propositus, the stereoselective disposition of warfarin was comparable with that of her brother ((S)-warfarin clearance = 16.2 ml min-1; and (S)/(R)-warfarin clearance ratio = 2.7).
一名30岁的黑人男性每天需要60毫克华法林才能产生治疗性抗凝反应(正常华法林剂量为2.5 - 10毫克/天;最大剂量为15毫克/天)。在排除依从性、饮食、同时服用的药物及任何胃肠道疾病等可能的促成因素后,怀疑存在遗传性华法林抵抗。对先证者、他的两个姐妹及13名对照黑人男性受试者进行了维生素K和维生素K环氧化物代谢情况的检查。在华法林治疗(5毫克/天)2周前后,分别给每位受试者静脉注射一剂(5毫克)维生素K。在华法林治疗的最后一天,还测量了每位受试者中(S)-和(R)-华法林的口服清除率。在所有受试者中,华法林治疗前后维生素K的平均(±标准差)全身清除率相似(治疗前为114±35毫升/分钟,治疗后为112±40毫升/分钟)。华法林治疗使所有受试者维生素K环氧化物的平均(±标准差)AUC值升高(治疗前为6.5±5.4微克·毫升-1·分钟,治疗后为139±78微克·毫升-1·分钟)。在先证者中,(S)-华法林的口服清除率(14.5毫升/分钟)及(S)/(R)-华法林的清除率比值(2.6)与对照组(分别为4.3±1.1毫升/分钟和1.2±0.2)相差超过7个标准差。在先证者的一个姐妹中,华法林的立体选择性代谢情况与其兄弟相当((S)-华法林清除率 = 16.2毫升/分钟;(S)/(R)-华法林清除率比值 = 2.7)。